Q1 2026 Turned out to Be my Second Worst Quarter

8899Nar
04-01 22:26

Q1 2026 turned out to be my second worst quarter since 2022, with a -14.5% return.

With many names down 30% in just one month, it was hard to do much better. My exposure to healthcare partially protected part of the portfolio.

Given the numerous opportunities, I preferred to rotate that part of the healthcare allocation into more offensive stocks in order to take advantage of the current discounts.

I’m extremely confident in my allocation and, based on my fair value estimates, I believe the portfolio can deliver a 24% CAGR over the next five years, a number from which a large part of my conviction comes.


For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.

🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now

Find out more here.

Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.

Click to access the activity

Other helpful links:

Macro Trend
Monetary policy, various types of price indices... Here is everything about the macro economy!
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment